Page 1 od 218 rezultati
In this double-blind, randomized trial, we compared the clinical efficacy of intralesional vinblastine (VNB) and 3% sodium tetradecyl sulfate (STS) in the treatment of oral Kaposi's sarcoma (OKS). Subjects with OKS were randomly assigned to receive a single intralesional injection of either VNB or
The cephalosporins are a family of semisynthetic antibiotics, some of which have structural features associated with substrates for the multidrug transporter, P-glycoprotein. The activity of a series of six cephalosporins in reversing multidrug resistance (MDR) was examined in MDR variants (Dx5
We have previously described the synthesis of a cytotoxic polymeric conjugate of spermine (Poly-SPM) which is able to inhibit the transport of polyamines (spermine, spermidine, and putrescine) into normal and malignant cells. Recent studies examining the toxicity of Poly-SPM in parental and
Fourteen patients with Kaposi's sarcoma (KSY were treated systemically with vinblastine sulfate in a low-dose regimen and compared with 23 patients reported in the medical literature. The therapeutic results in our series were excellent in terms of regression of cutaneous lesions. Vinblastine
Five cases of Kaposi sarcoma with vinblastine sulfate treatment were compared with 18 cases reported in the literature. Our experience with a low-dosage schedule emphasizes that toxicity is not necessary for a favorable result. Vinblastine seems to be an effective treatment for Kaposi sarcoma and,
BACKGROUND
Kaposi sarcoma (KS) is an acquired immune deficiency syndrome-defining condition in human immunodeficiency virus infection. Oral KS may produce local symptoms and require treatment. Palliation of oral lesions may be achieved with radiation therapy and chemotherapy. This review was
Kaposi's sarcoma (KS), the most frequent malignant neoplasm associated with acquired immunodeficiency syndrome, often involves the oropharynx and larynx. This study evaluated the efficacy of intralesional vinblastine sulfate injection in oropharyngeal and laryngeal KS. Twenty-four human
Kaposi's sarcoma is a common tumour in HIV-infected patients, frequently involving the oropharynx. Conventional treatment with radiotherapy is efficacious, but causes considerable discomfort. This paper illustrates a new technique of local injection of vinblastine into oral lesions, which combines
A patient with Kaposi's sarcoma of the oral cavity is reported. The intralesional use of vinblastine may be an effective treatment for small Kaposi's sarcoma lesions of the mouth or the skin that are painful or create cosmetic problems.
Treatment of palatal Kaposi's sarcoma (KS) with intralesional injection of vinblastine was seen to provide effective palliation. Of the ten patients studied, four had a 25% to 50% response, two 50% to 75% response, and four had 75% to 100% response with one or two intralesional injections of
OBJECTIVE
This study evaluated the use of intralesional vinblastine injections for the treatment of the intraoral lesions of Kaposi's sarcoma.
METHODS
Eighteen patients were treated with up to three intralesional injections of 0.1 mg/cc vinblastine.
RESULTS
All lesions responded to the local
The strong depressive effect of vinblastine on the rat sarcoma 45 growth and intensification of this effect by the combination of vinblastine treatment with the activation of the blood anticoagulating system (BAS) were found. Vinblastine had no negative effect on the BAS activation process and
Classic Kaposi sarcoma (KS) usually is a localized and slowly progressing disease that mainly affects elderly patients; therefore, local treatment generally is recommended. In this study, we evaluated the clinical efficacy of intralesional vinblastine (VNB) for the treatment of classic KS in 6
The aim of this study was to evaluate the efficacy of treatment of AIDS-related and non AIDS-related Kaposi's sarcoma (KS) using vinblastine (Velbé®). A retrospective study was conducted between January 1990 and December 2009 in the Department of Dermatology at the Lomé teaching hospital. The
A 34-year-old white man with the human immunodeficiency virus infection had a large Kaposi sarcoma lesion of his foot. This was treated with local radiation therapy consisting of 2700 rads administered in 15 fractions during a period of 28 days. Ten months later, the patient had painful disseminated